首页> 外文期刊>Pharmacogenetics >Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C.
【24h】

Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C.

机译:哺乳动物细胞中突变型人硫嘌呤S-甲基转移酶(TPMT)的增强蛋白酶体降解:TPMT * 2,TPMT * 3A,TPMT * 3B或TPMT * 3C继承的TPMT蛋白缺乏的机制。

获取原文
获取原文并翻译 | 示例
           

摘要

Inheritance of the TPMT*2, TPMT*3A and TPMT*3C mutant alleles is associated with deficiency of thiopurine S-methyltransferase (TPMT) activity in humans. However, unlike TPMT*2 and TPMT*3A, the catalytically active protein coded by TPMT*3C does not undergo enhanced proteolysis when heterologously expressed in yeast, making it unclear why this common mutant allele should be associated with inheritance of TPMT-deficiency. To further elucidate the mechanism for TPMT deficiency associated with these alleles, we characterized TPMT proteolysis following heterologous expression of wild-type and mutant proteins in mammalian cells. When expressed in COS-1 cells, proteins encoded by TPMT*2, TPMT*3A, and TPMT*3C cDNAs had significantly reduced steady-state levels and shorter degradation half-lives compared with the wild-type protein. Similarly, in rabbit reticulocyte lysate (RRL), these mutant TPMT proteins were degraded significantly faster than the wild-type protein. Thus, enhanced proteolysis of TPMT*3C protein in mammalian cells is in contrast to its stability in yeast, but consistent with TPMT-deficiency in humans. Proteolysis was ATP-dependent and sensitive to proteasomal inhibitors MG115, MG132 and lactacystin, but not to calpain inhibitor II. We conclude that all of these mutant TPMT proteins undergo enhanced proteolysis in mammalian cells, through an ATP-dependent proteasomal pathway, leading to low or undetectable levels of TPMT protein in humans who inherit these mutant alleles.
机译:TPMT * 2,TPMT * 3A和TPMT * 3C突变等位基因的遗传与人体内硫代嘌呤S-甲基转移酶(TPMT)活性不足有关。但是,与TPMT * 2和TPMT * 3A不同,当在酵母中异源表达时,由TPMT * 3C编码的催化活性蛋白不会进行增强的蛋白水解作用,这使得为什么这个共同的突变等位基因应该与TPMT缺陷的遗传相关联尚不清楚。为了进一步阐明与这些等位基因相关的TPMT缺乏的机制,我们表征了野生型和突变蛋白在哺乳动物细胞中异源表达后的TPMT蛋白水解。当在COS-1细胞中表达时,与野生型蛋白相比,由TPMT * 2,TPMT * 3A和TPMT * 3C cDNA编码的蛋白具有显着降低的稳态水平和较短的降解半衰期。同样,在兔网织红细胞裂解液(RRL)中,这些突变的TPMT蛋白的降解速度明显快于野生型蛋白。因此,哺乳动物细胞中TPMT * 3C蛋白增强的蛋白水解与其在酵母中的稳定性相反,但与人类TPMT缺乏相一致。蛋白水解是ATP依赖性的,并且对蛋白酶体抑制剂MG115,MG132和乳胞素敏感,但对钙蛋白酶抑制剂II不敏感。我们得出的结论是,所有这些突变的TPMT蛋白都通过ATP依赖的蛋白酶体途径在哺乳动物细胞中经历了增强的蛋白水解作用,从而导致在遗传这些突变的等位基因的人中TPMT蛋白水平较低或无法检测到。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号